作者
Roland Schmitz, Ryan M Young, Michele Ceribelli, Sameer Jhavar, Wenming Xiao, Meili Zhang, George Wright, Arthur L Shaffer, Daniel J Hodson, Eric Buras, Xuelu Liu, John Powell, Yandan Yang, Weihong Xu, Hong Zhao, Holger Kohlhammer, Andreas Rosenwald, Philip Kluin, Hans Konrad Müller-Hermelink, German Ott, Randy D Gascoyne, Joseph M Connors, Lisa M Rimsza, Elias Campo, Elaine S Jaffe, Jan Delabie, Erlend B Smeland, Martin D Ogwang, Steven J Reynolds, Richard I Fisher, Rita M Braziel, Raymond R Tubbs, James R Cook, Dennis D Weisenburger, Wing C Chan, Stefania Pittaluga, Wyndham Wilson, Thomas A Waldmann, Martin Rowe, Sam M Mbulaiteye, Alan B Rickinson, Louis M Staudt
发表日期
2012/10/4
期刊
Nature
卷号
490
期号
7418
页码范围
116-120
出版商
Nature Publishing Group UK
简介
Burkitt’s lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of such therapy precludes its use in the elderly and in patients with endemic BL in developing countries, necessitating new strategies. The normal germinal centre B cell is the presumed cell of origin for both BL and diffuse large B-cell lymphoma (DLBCL), yet gene expression analysis suggests that these malignancies may use different oncogenic pathways. BL is subdivided into a sporadic subtype that is diagnosed in developed countries, the Epstein–Barr-virus-associated endemic subtype, and an HIV-associated subtype, but it is unclear whether these subtypes use similar or divergent oncogenic mechanisms. Here we used high-throughput RNA sequencing and RNA interference screening to discover essential regulatory pathways in BL that cooperate with MYC, the defining oncogene of this cancer. In 70% of sporadic BL …
引用总数
20122013201420152016201720182019202020212022202320241564981081057994966874607337